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ABSTRACT
Background: Poorly described placebo/sham controls inhibit appraisal of active intervention benefits and 
harms. The 12-item Template for Intervention Description and Replication (TIDieR) checklist was 
developed to improve the reporting of active intervention components. The extent to which TIDieR is used 
to guide description of placebo or sham control is not known. 
Materials and methods: We examined all placebo/sham-controlled randomised trials published in 2018 in 
the top six general medical journals. We reported how many of the TIDieR checklist items they used to 
describe the placebo/sham control(s). We supplemented this with a sample of 100 placebo/sham-controlled 
trials from any journal, and searched Google Scholar to identify placebo/sham-controlled trials citing 
TIDieR.
Results: We identified 94 placebo/sham-controlled trials published in the top journals in 2018; none 
reported using TIDieR. On average 8 items were addressed, with placebo/sham control name (100%) and 
when and how much was administered (97.9%) most commonly reported. Some items (rationale, 8.5%, 
whether there were modifications, 25.5%) were less often reported. In our sample of less well cited 
journals, reporting was poorer (average of 6 items) and followed a similar pattern. Since TIDieR’s first 
publication, six placebo-controlled trials have cited it according to Google Scholar; two of these used the 
checklist to describe placebo controls.
Conclusions: Placebo and sham controls are poorly described within randomised trials, and TIDieR is 
rarely used to guide these descriptions. We recommend developing guidelines to promote better 
descriptions of placebo/sham control components within clinical trials.
Keywords: Placebo, TIDieR, reporting standards, placebo controlled, sham, trial
CTION
Placebo or sham controls come in many modalities, ranging from lactose pills and saline injections to sham 
acupuncture (of various types) and sham surgery. 1-5 These different placebos can have different effects. 6 
Even relatively simple drug placebos come in different formats (tablets, or capsules); they have different 
sizes, doses, 1 colors, 7 packaging, 8 and sizes. 9 They have different ingredients, 10,11 and sometimes they 
contain ingredients to mimic the side effects of the ‘active’ drug. 12 All of these differences can influence 
how effective they are. 
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A core function of placebo or sham control interventions is to provide a comparative benchmark against 
which the active interventions’ benefits and harms can be measured. 13 Such comparisons rely on the 
assumption that the placebo/sham intervention used is appropriate. 13 This assumption is sometimes 
unjustified. 14 For example, in trials of oseltamivir, the placebo contained dehydrocholic acid and dibasic 
calcium phosphate dehydrate. This was presumably to mimic the bitter taste of the active intervention 
(oseltamivir powder) and thus maintain blinding. 15 However, dehydrocholic acid can cause gastrointestinal 
symptoms, as can oseltamivir. 16 Hence, while placebo controlled trials of oseltamivir often found an 
increased risk of gastrointestinal symptoms in the oseltamivir group compared with the placebo group, this 
was probably an underestimate of the true incidence of the harms. 14
Some placebo or sham interventions can also lead to exaggerated active intervention effects. For example, a 
2016 review (including 1973 trials) found that up to 64% of placebo control interventions were not 
matched in terms of physical properties. 17 Lack of matching makes placebos identifiable, thus unblinding 
the trial. Unblinded patients who know they are receiving a ‘mere’ placebo may have lower expectations 
about recovery. These lower expectations, in turn, can affect the trial outcome, especially when symptoms 
are subjective and susceptible to suggestion. As evidence for the influence of this ‘expectation bias’, a 2004 
systematic review showed that intervention effects were smaller when expectation bias was reduced. 18 
The extent to which the assumption that placebo/sham controls are appropriate (leading to mistaken 
estimates of benefit or harm) is unknown because placebo/sham components are rarely reported. A 
systematic review found that disclosing placebo/sham ingredients is rare: 8.2% for pills, and 26.7% for 
injections. 11 Inadequate placebo/sham control description stands in the way of trial replication, appraising 
the validity of the apparent active intervention benefits and harms, and for evaluating whether the 
placebo/sham was well matched (to assess whether blinding was likely to have been achieved). 17
The Template for Intervention Description and Replication (TIDieR) checklist was developed to improve 
the problem of poor reporting of interventions, and it is mainly used to guide the description of active 
interventions. 19 The extent to which TIDieR is appropriate or being used to guide the reporting of placebo 
and sham interventions is unknown.
AIMS
Our main aim was to determine the extent to which placebo/sham-controlled trials report placebo/sham 
interventions using TIDieR reporting items. A secondary aim was to check whether placebo/sham-
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controlled trials that use TIDieR to report active interventions also use TIDieR to report the placebo/sham 
intervention.
MATERIALS
Selection of articles
We followed the methodology used to develop TIDieR, 20 and examined all relevant trials published in six 
general medical journals with the highest impact factors (New England Journal of Medicine, JAMA, 
Lancet, Annals of Internal Medicine, PLOS Medicine, and BMJ) in a single year (2018) (see Appendix 1). 
We supplemented this main sample with an additional search (see Appendix 2), and selected a pseudo-
random sample of 100 placebo/sham-controlled trials published in any journal (including those with lower 
impact factors) in. This was achieved by identifying the first 100 alphabetically ordered records of 
placebo/sham-controlled trials published in 2018. This allowed us to see whether there is a difference in 
placebo control reporting between the higher cited journals (many of which claim to support TIDieR), and 
other journals. For our secondary aim of checking whether placebo/sham controlled trials that used TIDieR 
to describe the active intervention, also used TIDieR to describe placebo/sham interventions, we searched 
Google Scholar to identify any placebo/sham controlled randomised trial that cited TIDieR (no date/time 
limit) (see Appendix 3).
For all samples, we read through the main study manuscript and sought additional supplementary material 
(including protocols and trial registrations) that were available and extracted whether the placebo/sham 
control(s) had been described according to each of the 12 TIDieR checklist items. We did so whether or not 
the trial reported using TIDieR. In some studies, the placebo or sham control was reported to be the same 
as / equivalent to the active intervention other than certain (characteristic) features. We interpreted those 
reports charitably and appealed to the relevant descriptions of the active interventions as surrogate 
descriptions of the placebo/sham controls. We also extracted data about the type of intervention under 
investigation (drug pill, drug injection, physiotherapy, psychology, surgery, or complementary and 
alternative). JH piloted the extraction sheet, and three researchers (RW, KB, CM) subsequently extracted 
the data. Discrepancies were resolved by discussion between authors (JH, RW, KB, CM).
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Descriptive statistics consisting of frequencies and percentages were used to describe whether studies 
adhered to individual items (n=12) in the TIDieR checklist. Excel was used to analyse the data 
descriptively.
RESULTS 
Search results
Figure 1 shows the search results and reasons for exclusion for each of our three samples. The search for 
our main sample yielded 123 records. 21 were excluded for not being published in the top six journals, two 
for being published in 2019 rather than 2018, and four for not being placebo-controlled trials. A further two 
were subsequently excluded as they were secondary analyses of trials already published. 
For our second sample (of placebo-controlled trials published in any journal in 2018), our search yielded 
3563 records in PubMed. To reach 100 trials eligible for inclusion, we screened the title and abstract of the 
first 126 alphabetically ordered reports. 12 of the 126 were not placebo-controlled trials, and a further 14 
did not meet our inclusion criteria.
Of the 1654 studies identified on Google Scholar that cite TIDieR, six were placebo/sham-controlled trials, 
two of which mentioned using TIDieR to report the placebo/sham control.
[Figure 1 about here]
Intervention type
The majority of placebo controls (90.4%) in our main sample related to trials investigating pharmacological 
interventions , followed by complementary and alternative medicine (CAM, 6.4%) such as acupuncture, 
then surgery (2.1%) and physiotherapy (1.1%). In our second sample of trials published in any journal, a 
smaller percentage of trials were pharmacological (61%), with a greater number of CAM (23%) and other 
intervention types including  physiotherapy (4%), laser treatment (3%), and stimulation (3%). The second 
sample also included trials using‘other’ intervention types including  ultrasound, tobacco , and  devices 
(see Table 1). 
Among the placebo/sham controlled trials that cited using TIDieR, none were pharmacological 
interventions; they were  exercise (n=3), CAM (n=1), physiotherapy (n=1) and  laser treatment (n=1).
[Table 1 about here]
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ieR checklist
Table 2, and Figure 2 show the percentage of trials that addressed this item in their primary reports and/or 
any supplementary materials for each of the checklist items. None of our two samples of placebo-controlled 
trials published in 2018 mentioned using TIDieR. None of the trials from any of the samples fully adhered 
to all 12 TIDieR checklist items for reporting placebo/sham controls. 
In our first sample of studies published in the top 6 medical journals, the included studies reported over half 
of the items (average 8, standard deviation =1.8). All trials included the brief name of the placebo, and 
most included details about the materials (68.1%), procedure (92.6%), how and where it was administered 
(68.1%) and, when and how much was administered (97.9%). However, reporting was poorer for: 
providing a rationale for the control (8.5%), who provided the sham intervention (45.7%) or whether it was 
modified (25.5%).
For our second sample (placebo-controlled trials published in 2018 which were not restricted to the top 
journals) reporting was poorer (average number of items included = 6, standard deviation =1.7), but 
followed a similar pattern. Most trials included the brief name of the placebo (98%), how it was 
administered (82%), and when and how much was administered (89%). However, fewer than half the 
sample reported planned (20%) or actual (12%) fidelity, whether it was tailored (15%), a rationale for the 
control (7%), or whether it was modified (4%)
For the six trials that mentioned using TIDieR to describe the active intervention, an average of 8 (standard 
deviation =2.5) items were reported, and again a similar pattern was observed. The name of the placebo and 
administration procedures were reported, whereas items concerning why that choice of placebo tailoring, 
modifications and adherence were not. We have provided abstractions of these articles for each of TIDieR 
items in Appendix 4 to show how these items were reported. 
[Table 2 about here]
[Figure 2 about here]
USSION
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Summary of findings
TIDieR is rarely used to describe placebo/sham interventions, and reporting of placebo and sham 
interventions is poor. TIDieR items regarding WHAT, WHO, HOW, WHERE, WHEN and HOW MUCH 
are the most adequately addressed which are likely to be explained by default when authors provide 
information about the intervention and control conditions as required by CONSORT. 21  However, more 
specific information as requested in TIDieR such as details of the components of the placebo/sham control, 
rationale for the placebo, whether it was modified, and whether it was adhered to is rarely reported for 
placebo controls even in trials that report its use.
Comparison with other related studies
In a 2010 study, Golomb et al. 11 found that disclosure of the composition of placebos varied from 8.2-
26.7% (depending on placebo type). Hoffman et al. (2013) found that fewer than half of ‘active’ 
interventions were adequately described in 39% of trial reports. 20  Based on our limited sample, it seems 
that reporting of placebo components has improved slightly in the last decade. Our study also revealed that 
adequate reporting of placebo or sham control interventions is poorer than adequate reporting of active 
interventions. 22,23
Strengths and limitations
This is the first study to investigate the extent to which TIDieR is being used to describe placebo or sham 
control interventions. A limitation is that our samples did not contain any trials of psychological or 
behavioural interventions. This may be due to our use of PubMed a primarily clinical database, but it does 
not apply to our Google Scholar search for trials that cite TIDieR. With psychological or behavioural 
interventions, the control arm often consists of minimal intervention, treatment as usual or no intervention, 
which are not necessarily placebo/sham controls. Nonetheless, these types of studies have been shown to be 
no better at reporting intervention methods than pharmacological trials. 24 Moreover, the majority of our 
sample are placebo-controlled trials of pharmacological interventions which is a more regulated field. 
Hence, by not including trials with psychological/behavioural interventions, we may have underestimated 
the problem with failure to disclose placebo/sham components. Future research on how to improve 
reporting of placebo/sham interventions should ensure that any reporting guidance for placebo/sham 
controls applies to behavioural interventions.
Another limitation concerns the fact that our second sample of studies used alphabetical ordering to 
generate a proxy randomised sample of studies. As such this sample of studies may not be representative of 
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all trials published that year. This limitation does not apply to our main sample. In addition, 11 of the 
studies included in our second sample of trials published in any journal, were in fact published in the top 6 
general medical journals, hence there is a degree of overlap, and these studies may have inflated the 
TIDieR reporting standards in this sample. Our sample of 100 trials from any journal provides a more 
accurate description of reporting across journal types.
Recommendations for future research
In order to perform their function of providing an adequate benchmark against which the benefits and 
harms of active interventions can be measured, placebo or sham components should be described 
rigorously. Researchers should investigate why current guidelines for reporting ‘active’ interventions 
(TIDieR) are rarely used, even among journals such as the BMJ who allegedly require its use 25. 
In addition, TIDieR may require adaptation for placebo or sham controls. Some items might not apply, 
others may require additional emphasis, and some additional items could be required. For example, it may 
be less important to include a rationale for the placebo, as it can be assumed to be to control for certain 
(‘characteristic’) features of the active intervention. 13 To achieve this function, successful blinding may be 
required. 26,27 Relatedly, appraising  the estimate of intervention harms requires that placebo controls 
designed to be ‘active’ (containing ingredients that mimic side-effects or taste of the active intervention) 12 
should be reported as such. It may also be necessary to explicitly relate the reporting of the placebo/sham to 
the reporting of the active intervention, especially as the current prompts for the TIDieR items only refer to 
the ‘intervention’ which authors may interpret as only the ‘active’ intervention under investigation rather 
than the placebo/sham control as well. Finally, any adaptation or addition to current intervention reporting 
for placebo or sham controls should minimize additional burden to researchers, 28 in order to avoid barriers 
to implementation.
Conclusion
The extent to which placebo or sham interventions are reported within clinical trials—including trials 
reported in journals that require use of guidelines to describe active interventions—is poor. This inhibits 
assessing the benefits and harms of active interventions and trial replication. Designing and promoting 
reporting standards for placebo and sham controls is required.
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Figure 1. Flow diagram of study selection for each of the three samples
Figure 2. Percentage of placebo-controlled trials that reported each TIDieR item
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TABLES
Table 1. Categories of interventions of included trials
Intervention category Sample 1 (% 
reporting among 
sample of placebo-
controlled trials 
published in top 
journals (n=94))
Sample 2 (% 
reporting among 
sample of 
placebo-
controlled trials 
(n=100))
Sample 3 (% 
reporting among 
placebo-controlled 
trials that reported 
using TIDieR 
(n=6))
Pharmacological (e.g. placebo drug 
pill/injection)
90.4 61 -
Sham exercise - - 50
CAM (e.g. sham acupuncture, 
dietary/herbal supplements)
6.4 23 16.7
Sham physiotherapy 1.1 4 16.7
Sham laser treatment - 3 16.7
Stimulation (e.g. sham rTMS) - 3 -
Sham surgery 2.1 - -
Other - 6 -
Note: CAM= complementary and alternative medicine, rTMS = repetitive transcranial magnetic stimulation
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Table 2. Adherence to individ ms
Sample 1
% reporting 
among sample 
of placebo-
controlled trials 
published in top 
journals (n=94)
Sample 2 
% reporting 
among sample of 
placebo-
controlled trials 
(n=100)
Sample 3
% reporting 
among placebo-
controlled trials 
that reported 
using TIDieR 
(n=6) 
Mentioned using TIDieR 0 0 100
TIDieR item
Brief name 100 98 100
Why 8.5 7 16.7
What (materials) 68.1 60 33.3
What (procedures) 92.6 65 100
Who provided 45.7 59 83.3
How 68.1 82 83.3
Where 68.1 63 100
When and how much 97.9 89 100
Tailoring 59.6 15 50
Modifications 25.5 4 33.3
How well (planned 
adherence/fidelity assessment)
55.3 20 33.3
How well (actual 
adherence/fidelity)
54.3 12 33.3
Addressed all TIDieR items 0 0 0
Mean number of items addressed 7.5 (SD 1.8) 5.7 (SD 1.7) 7.7 (SD 2.5)
SD= standard deviation 
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SUPPLEMENTARY MATERIAL
Appendix 1. PubMed Search Strategy for Placebo Controlled Trials in Most Widely Cited Journals 
(search on 10th May 2019)
Appendix 2. PubMed Search Strategy (search on 6th February 2019)
Appendix 3. Google Scholar Search (search on 21st February 2019)
Appendix 4. Extractions for the 6 studies u
 Search results 
(title and abstracts 
reviewed) 
n=126 
Excluded = 12 
(not placebo-
controlled trial) 
Full text papers 
retrieved, and 
eligibility checked 
n=114 
Included 
n=100 
Excluded = 14 
Secondary analysis of 
a trial (n=5) 
Protocol (n=4) 
Full text not available 
(n=4) 
Commentary (n=1) 
 
Search results 
(title and abstracts 
reviewed) 
n=123 
Excluded = 27 
Not top 6 journal 
(n=21) 
Not published in 2018 
(n=2) 
Not placebo- 
controlled trial (n=4) 
 
Full text papers 
retrieved, and 
eligibility checked 
n=96 
Included 
n=94 
Excluded = 2 
(secondary analysis 
of a trial) 
Search results 
(title and abstracts 
reviewed) 
n=1654 
Excluded = 1648 
(not placebo-
controlled trial) 
Full text papers 
retrieved, and 
eligibility checked 
n=6 
Included 
n=6 
a) Main sample of trials reported in top 
6 medical journals in 2018 
b) Secondary random sample of trials 
published in 2018 
c) Secondary sample of trials reporting 
using TIDieR 
Figure 1. Flow diagram of study selection for each of the three samples 
eci_13169_f1.docx
This	article	is	protected	by	copyright.	All	rights	reserved
 Figure 2. Percentage of placebo/sham-controlled trials that reported each TIDieR item 
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